UCART CS1
Alternative Names: UCART-CS1; UCART-CS1ALatest Information Update: 10 May 2023
At a glance
- Originator Cellectis
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 04 May 2023 UCART CS1 is still in phase-I trials for Multiple-myeloma (Second-line therapy or greater) is still ongoing in USA
- 04 May 2023 Cellectis terminates phase-I MELANI-01 trials for Multiple-myeloma (Second-line therapy or greater) in USA
- 28 Mar 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in USA (Parenteral)